Cargando…

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma

Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Mistro, Greta, Lucarelli, Philippe, Müller, Ines, De Landtsheer, Sébastien, Zinoveva, Anna, Hutt, Meike, Siegemund, Martin, Kontermann, Roland E., Beissert, Stefan, Sauter, Thomas, Kulms, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218484/
https://www.ncbi.nlm.nih.gov/pubmed/30416750
http://dx.doi.org/10.1038/s41540-018-0075-y
_version_ 1783368460360744960
author Del Mistro, Greta
Lucarelli, Philippe
Müller, Ines
De Landtsheer, Sébastien
Zinoveva, Anna
Hutt, Meike
Siegemund, Martin
Kontermann, Roland E.
Beissert, Stefan
Sauter, Thomas
Kulms, Dagmar
author_facet Del Mistro, Greta
Lucarelli, Philippe
Müller, Ines
De Landtsheer, Sébastien
Zinoveva, Anna
Hutt, Meike
Siegemund, Martin
Kontermann, Roland E.
Beissert, Stefan
Sauter, Thomas
Kulms, Dagmar
author_sort Del Mistro, Greta
collection PubMed
description Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies.
format Online
Article
Text
id pubmed-6218484
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62184842018-11-09 Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma Del Mistro, Greta Lucarelli, Philippe Müller, Ines De Landtsheer, Sébastien Zinoveva, Anna Hutt, Meike Siegemund, Martin Kontermann, Roland E. Beissert, Stefan Sauter, Thomas Kulms, Dagmar NPJ Syst Biol Appl Article Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies. Nature Publishing Group UK 2018-11-05 /pmc/articles/PMC6218484/ /pubmed/30416750 http://dx.doi.org/10.1038/s41540-018-0075-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Del Mistro, Greta
Lucarelli, Philippe
Müller, Ines
De Landtsheer, Sébastien
Zinoveva, Anna
Hutt, Meike
Siegemund, Martin
Kontermann, Roland E.
Beissert, Stefan
Sauter, Thomas
Kulms, Dagmar
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title_full Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title_fullStr Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title_full_unstemmed Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title_short Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
title_sort systemic network analysis identifies xiap and iκbα as potential drug targets in trail resistant braf mutated melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218484/
https://www.ncbi.nlm.nih.gov/pubmed/30416750
http://dx.doi.org/10.1038/s41540-018-0075-y
work_keys_str_mv AT delmistrogreta systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT lucarelliphilippe systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT mullerines systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT delandtsheersebastien systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT zinovevaanna systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT huttmeike systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT siegemundmartin systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT kontermannrolande systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT beissertstefan systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT sauterthomas systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma
AT kulmsdagmar systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma